Breast Cancer

The FDA granted fast track designation to CT-0508 for treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2.

Women who miss cancer screenings face higher morbidity and mortality risks, and race may indicate who is more likely to get those screenings, according to a study presented at the North American Menopause Society Annual Meeting.

The addition of pembrolizumab to first-line chemotherapy led to statistically significant improvement in PFS and OS among patients with PD-L1-positive metastatic triple-negative breast cancer, according to results of the KEYNOTE-355 trial.

Hispanic adults had lower rates of overall cancer incidence between 2014 and 2018, but higher rates of liver and stomach cancers compared with whites, according to study results published in CA: A Cancer Journal for Clinicians.

The risk for CAD in women with stage I or II breast cancer who received left-sided radiation therapy may be more than twofold greater compared with those who received right-sided radiation.

Patients with pretreated locally advanced or metastatic HER2-positive breast cancer had significantly longer PFS after treatment with [vic-]trastuzumab duocarmazine vs. physician’s choice of treatment, according to study results.

The addition of carboplatin to paclitaxel improved pathologic complete response and EFS with no increase in secondary malignancies among patients with triple-negative breast cancer, randomized phase 3 trial results showed.

By reading mammograms immediately, providers can accelerate diagnostic workups and reduce racial and ethnic disparities in care, according to a study published in the American Journal of Roentgenology.

Black and Hispanic women had a higher risk than white women for ED visits within 90 days after breast cancer surgery, according to a population-based study published in Breast Cancer Research and Treatment.

The FDA cleared an investigational new drug application for a T-cell receptor therapy designed to treat adults with solid epithelial cancers that express Kita-Kyushu lung cancer antigen 1.